Exelixis (MIL:1EXEL) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1EXEL Exelixis Inc MIL:1EXEL
74 GF Score
Price €45.90
GF Value €40.82
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exelixis Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MIL:1EXEL vs MDGL, AXSM, ARWR: Short Percentage of Float Comparison

For the Biotechnology subindustry, Exelixis's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exelixis Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Exelixis's Short Percentage of Float falls into.


MIL:1EXEL
74GF Score
Exelixis Inc MIL:1EXEL
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exelixis (MIL:1EXEL) Overvalued in 2026?

Based on GuruFocus' analysis, Exelixis stock appears to be overvalued. The current stock price of €45.90 is trading 12.4% above its estimated GF Value™ of €40.82. GuruFocus considers Exelixis to be Modestly Overvalued.

Key valuation signals for MIL:1EXEL:

  • Short Percentage of Float:
  • GF Value™: €40.82 vs. price of €45.90 (12.4% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the MIL:1EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exelixis Business Description

Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
74GF Score

Get the complete analysis for MIL:1EXEL

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.90
Price
€40.82
GF Value